Scinai Immunotherapeutics LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
Scinai Immunotherapeutics reports continued operating losses and substantial doubt about its ability to continue as a going concern, despite growing CDMO revenues and strategic R&D advancements.
NASDAQ
20-F: Scinai Immunotherapeutics Outlines Strategy in Annual Report, Focuses on CDMO and NanoAb Development
Scinai Immunotherapeutics shifts focus to CDMO services and NanoAb development, aiming for long-term growth and shareholder value.
NASDAQ
Scinai Immunotherapeutics details its financial performance for 2023 and provides an overview of its strategic focus on I&I therapeutics and CDMO services.